Stéphane Bancel, Moderna CEO (Charles Krupa/AP Images)

Mod­er­na touts 'su­pe­ri­or' an­ti­body lev­els against Omi­cron for au­tho­rized Covid-19 bi­va­lent boost­er

In Sep­tem­ber, Mod­er­na re­ceived FDA emer­gency use au­tho­riza­tion for its BA.4/BA.5-tar­get­ing bi­va­lent boost­er vac­cine, mR­NA-1273.222, based on pre­clin­i­cal da­ta for the shot as well as Phase II/III clin­i­cal tri­al da­ta study­ing a sim­i­lar bi­va­lent boost­er tar­get­ing the Omi­cron BA.1 sub­vari­ant.

Now, the mR­NA biotech says it has pos­i­tive clin­i­cal da­ta on mR­NA-1273.222 it­self to bur­nish the pro­file of the Covid-19 vac­cine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.